drugset
drugset / Trial / NCT00763503

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis

NCT00763503 ↗

Phase 2 Completed 26 enrolled Galderma R&D
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label study to assess systemic plasma levels of calcitriol, calcium homeostasis and safety in adults with plaque-type psoriasis under conditions of maximized use of CD 2027 3µg/g oily spray twice daily (6 g daily), applied to 20% of BSA for 3 weeks. There are a total of six visits: Pre-treatment period (Day -15, Day -8 and Day -1) and Treatment period (Day 1/ Baseline, Day 15 and Day 22).

Timeline

Start
2008-09
Primary completion
2008-12
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcitriol Small molecule 3 unknown Topical

Indications

psoriasis